An Explainable AI Model for Predicting the Recurrence of Differentiated Thyroid Cancer

High accuracy doesn't guarantee clinical readiness: While the model achieved 96% accuracy on test data, the paper doesn't discuss real-world validation, potential biases in the dataset, or how the 4% error rate translates to actual patient harm—critical factors before deploying AI in clinical settings.

Explainability techniques are essential but not sufficient: The use of LIME and Morris Sensitivity Analysis to interpret the model's decisions represents responsible AI practice, but the paper provides no specific examples of what insights these methods revealed or how clinicians would actually use this information to make treatment decisions.

Personalized medicine requires more than prediction: The stated goal of "personalized treatment approaches" based on recurrence predictions needs clarification—the paper doesn't explain what different treatments would be recommended for high-risk versus low-risk patients, or whether such differentiated approaches are evidence-based.

Dataset transparency is missing: The paper doesn't describe the dataset's size, demographic composition, geographic origin, or potential biases, making it impossible to assess whether the model's performance would generalize to diverse patient populations or if it might perpetuate existing healthcare disparities.

Clinical validation and physician involvement are absent: There's no mention of whether oncologists reviewed the model's predictions, tested it against their own clinical judgment, or participated in developing the interpretability approach—steps necessary to ensure the tool actually improves patient outcomes rather than just automating existing practices.